• Kyodo

  • SHARE

The health ministry will order a business suspension of around 15 days for a Japanese unit of Swiss pharmaceutical maker Novartis AG for not reporting serious side effects of its drugs, sources close to the matter said on Monday.

Tokyo-based Novartis Pharma K.K. would be the first pharmaceutical company in Japan to receive such an order from the Ministry of Health, Labor and Welfare for breaching the duty of promptly reporting serious drug side effects, according to the sources.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW